A Milan-based biotech company developing novel treatments for difficult to treat genetic conditions.
Aptadir Therapeutics has raised €40M across 1 funding round from 5 investors, most recently a Seed round in Sep 2026. Based in Milan, Italy; active in Healthtech. Data as of 29 Sept 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-09-29 | Seed | €40M |
| 4BIO Capital,CDP Venture Capital,CE-Ventures,Extend,XGEN Venture |
| View deal → |
